BioVendor Presents Latest Innovations in Immunodiagnostics and Molecular Diagnostics at Medlab Middle East 2023

At this year’s Medlab Middle East, BioVendor is presenting its growing CLIA portfolio of parameters, Microblot-Array multiplex diagnostics in microtiter plate format, other technologies, such as the revolutionary NGS technology fastGEN, and its unique methods using microRNAs. BioVendor is highlighting its CLIA portfolio of assays with a constantly growing number of parameters developed for the cutting-edge analyzer KleeYa. BioVendor Group’s CLIA portfolio currently includes 41 unique parameters. Its MxA Human Protein is the flagship of a total of 41 unique CLIA parameters that expand the possibilities of laboratories.

BioVendor is also highlighting Microblot-Array (MBA), a new generation of unique, immunoblot array in a microtiter plate format. It is designed for efficient multiplex diagnostics, enabling the simultaneous detection of multiple markers which can save time and lower costs. The Microblot-Array is a comprehensive solution for fast and accurate multiplex diagnostics. A combination of BLOT principle and ELISA workflow allows the use of existing laboratory equipment and keeps the setup costs down.

At Medlab Middle East 2023, BioVendor is showcasing its new technology fastGEN for examination of the mutation status of oncomarkers in samples. The technology is base on ultra-deep sequencing of short amplicons obtained by a single polymerase chain reaction with special tagged hybrid primers. The fastGEN technology is simple, ultra-sensitive, specific and effective - it is perfectly adapted to diagnostics and offers new advantages for clinical material. BioVendor highlighted its user-friendly diagnostic kits with software solution for KRAS, NRAS, BRAF, EGFR, IDH 1/2, POLE and CFTR genes with excellent analytical parameters and extremely fast processing.

Additionally, BioVendor is demonstrating its complete solution for miRNA/sncRNA projects starting with isolation, followed by screening for proper targets and final quantification of them. The small regulatory molecules, called microRNA or miRNA, have become emerging biomarkers for research in all fields of medical and biological sciences. This new miRNA regulatory domain empowers R&D, identifies novel disease biomarkers in biofluids and tissues and develops non-invasive screening and diagnostic tests. Using miRNA as pathological biomarkers is technically feasible, highly specific and sensitive from the earliest stages of the disease. BioVendor offers specific technologies based on patented RT-qPCR for sensitive detection and quantification of miRNA molecules. The technologies use multiplex detection format already used in life sciences research and clinical diagnostic applications.

Related Links:
BioVendor Group